ALK and non-small cell lung carcinoma: A phase I trial in patients with advanced ALK-positive NSCLC demonstrated that crizotinib is associated with higher response rates and improved survival compared to that of crizotinib-naive controls (14), and as a result, received approval from FDA in the US and Health Canada in 2011 for use in this patient population.